Kokou Atchou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kokou Atchou has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Povi Lawson-Evi
Pathophysiology, Bioactive Substances and Safety Research Unit, Faculty of Sciences, University of Lome, Postbox 1515, Togo
4 shared publicationsKwashie Eklu-Gadegbeku
Pathophysiology, Bioactive Substances and Safety Research Unit, Faculty of Sciences, University of Lome, Postbox 1515, Togo
3 shared publications- Karkala Sreedhara Ranganath Pai
Department of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India
2 shared publications - Aboudoulatif Diallo
Department of Toxicology, Faculty of Health Sciences, University of Lome, Lome, Togo
1 shared publication Ajmal Nassar
Department of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India; Department of Pharmacology, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi, Kerala, 682041, India
1 shared publication- Anusha Govindula
Department of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India
1 shared publication
Latest Publications
- Open Access
- 1 June 2026
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 828, 154083
Precision targeting of SRC signaling in glioblastoma: Mechanistic insights and bilosome nanotechnology
- 1 June 2026
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 828, 154083
Open AccessPrecision targeting of SRC signaling in glioblastoma: Mechanistic insights and bilosome nanotechnology
- Open Access
- 14 May 2026
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1026, 178971
In silico and in vitro evaluation of risedronate as a DKK1 antagonist: Implications for neuroprotection through DKK1–LRP6 modulation
- 14 May 2026
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1026, 178971
Open AccessIn silico and in vitro evaluation of risedronate as a DKK1 antagonist: Implications for neuroprotection through DKK1–LRP6 modulation
- Open Access
- 24 October 2024
- Published by MDPI AG in Preprints.org
Pharmacological Study of Amaranthus spinosus L. Root Extract on High-Fat Diet and Low-Dose Streptozocin-Induced Type 2 Diabetes Complications in Rats
Diabetes complications appear with the severity of hyperglycemia and the age of the disease. In type 2 diabetes mellitus (T2DM), herbal medicines are also effective in reducing hyperglycemia and can be used for this purpose to manage complications. This study aimed to prove the effectiveness of Amaranthus spinosus root extract on type 2 diabetes (T2D) and its microvascular complications. A high-fat diet and low-dose streptozocin were used for 20 days to induce T2D syndrome and complications in rats. The validated animal models were treated orally with the dried hydroethanolic extract of A. spinosus for three weeks; then the hematological, biochemical, and histological markers were evaluated. The results showed that the extract at a dose of 500 mg/kg bw was effective against diabetes and its complications. This effectiveness was linked to a significant reduction (p < 0.0001) in basal blood glucose, tissue oxidative stress, serum cardiovascular and hepato-renal markers, and an improvement in insulin secretion and utilization. The protective activity of the extract against macular edema and renal fibrosis was confirmed by histopathological examinations. These findings prove that A. spinosus root extract contains bioactive compounds that may be useful in preventing or reversing diabetic retinopathy and renal fibrosis.
- 24 October 2024
- Published by MDPI AG in Preprints.org
Open AccessPharmacological Study of Amaranthus spinosus L. Root Extract on High-Fat Diet and Low-Dose Streptozocin-Induced Type 2 Diabetes Complications in Rats
Diabetes complications appear with the severity of hyperglycemia and the age of the disease. In type 2 diabetes mellitus (T2DM), herbal medicines are also effective in reducing hyperglycemia and can be used for this purpose to manage complications. This study aimed to prove the effectiveness of Amaranthus spinosus root extract on type 2 diabetes (T2D) and its microvascular complications. A high-fat diet and low-dose streptozocin were used for 20 days to induce T2D syndrome and complications in rats. The validated animal models were treated orally with the dried hydroethanolic extract of A. spinosus for three weeks; then the hematological, biochemical, and histological markers were evaluated. The results showed that the extract at a dose of 500 mg/kg bw was effective against diabetes and its complications. This effectiveness was linked to a significant reduction (p < 0.0001) in basal blood glucose, tissue oxidative stress, serum cardiovascular and hepato-renal markers, and an improvement in insulin secretion and utilization. The protective activity of the extract against macular edema and renal fibrosis was confirmed by histopathological examinations. These findings prove that A. spinosus root extract contains bioactive compounds that may be useful in preventing or reversing diabetic retinopathy and renal fibrosis.
- Open Access
- 2 September 2023
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 35, 101541
Improvement of microvascular complications in STZ-diabetic rats treated with Pterocarpus erinaceus Poir. extract
- 2 September 2023
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 35, 101541
Open AccessImprovement of microvascular complications in STZ-diabetic rats treated with Pterocarpus erinaceus Poir. extract
- Open Access
- 1 November 2021
- Published by Elsevier in Phytomedicine Plus
- Vol. 1 (4)
Safety assessment of the dried hydroethanolic extract of Pterocarpus erinaceus Poir. stem bark
- 1 November 2021
- Published by Elsevier in Phytomedicine Plus
- Vol. 1 (4)
Open AccessSafety assessment of the dried hydroethanolic extract of Pterocarpus erinaceus Poir. stem bark
- Open Access
- 21 July 2021
- Published by Springer Nature in Clinical Phytoscience
- Vol. 7 (1) , 1-9
Toxicological evaluation of the dried hydroethanolic extract of Amaranthus spinosus L. roots in Artemia salina larvae and Sprague Dawley rats
Background: Amaranthus spinosusis a medicinal plant used in traditional medicine to treat several diseases including diabetes and its complications. The aim of this study was to prove the safety of the plant in animal health.Methods: The dry extract was obtained following the hydroethanolic extraction ofA. spinosusroots. The cytotoxicity was evaluatedin vitroby incubatingArtemia salinalarvae with the extract for 24 h.In vivotoxicity was assessed in Sprague Dawley rats. A single dose of 5000 mg/kg bw of extract was administered orally to female rats in acute toxicity and observed for 14 days for mortality and signs of toxicity. In subchronic toxicity, extract doses of 500 and 1000 mg/kg bw were administered orally to male and female rats for 28 consecutive days and observed for previous signs. Body weight was recorded daily and blood glucose levels every week. On day 29, blood was collected for biochemical and hematological studies. Organs were then exised for gross autopsy and histopathological examination.Results: Thein vitrostudy showed that the extract had a LC50 = 1.178 mg/mL in larvae and was considered to be non-cytotoxic. Oral administration of extract at a single dose of 5000 mg/kg bw did not cause any mortality or sign of toxicity in gross necropsy. In subchronic oral toxicity, repeated doses of 500 and 1000 mg/kg bw of extract, did not also cause any mortality or significant change in body weight, relative weight of vital organs. Furthermore, hematological and biochemical parameters and histopathological examination did not show any significant change. The observed decrease in blood glucose levels did not correlate with organ damage and supports the safety of the plant. However, the reduction of LDL-cholesterol has shown that the extract can prevent cardiovascular disease.Conclusions: This finding demonstrated thatA. spinosusroot is non-toxic with a LD50 > 5000 mg/kg bw. Thus, the extract can be used for cutaneous and subchronic oral administration at doses ≤ 1000 mg/kg bw. However, further studies such as embryo/fetotoxicity, genotoxicity and neurotoxicity will be needed to prove the safety of chronic administration of the extract in patients and fetuses.
- 21 July 2021
- Published by Springer Nature in Clinical Phytoscience
- Vol. 7 (1) , 1-9
Open AccessToxicological evaluation of the dried hydroethanolic extract of Amaranthus spinosus L. roots in Artemia salina larvae and Sprague Dawley rats
Background: Amaranthus spinosusis a medicinal plant used in traditional medicine to treat several diseases including diabetes and its complications. The aim of this study was to prove the safety of the plant in animal health.Methods: The dry extract was obtained following the hydroethanolic extraction ofA. spinosusroots. The cytotoxicity was evaluatedin vitroby incubatingArtemia salinalarvae with the extract for 24 h.In vivotoxicity was assessed in Sprague Dawley rats. A single dose of 5000 mg/kg bw of extract was administered orally to female rats in acute toxicity and observed for 14 days for mortality and signs of toxicity. In subchronic toxicity, extract doses of 500 and 1000 mg/kg bw were administered orally to male and female rats for 28 consecutive days and observed for previous signs. Body weight was recorded daily and blood glucose levels every week. On day 29, blood was collected for biochemical and hematological studies. Organs were then exised for gross autopsy and histopathological examination.Results: Thein vitrostudy showed that the extract had a LC50 = 1.178 mg/mL in larvae and was considered to be non-cytotoxic. Oral administration of extract at a single dose of 5000 mg/kg bw did not cause any mortality or sign of toxicity in gross necropsy. In subchronic oral toxicity, repeated doses of 500 and 1000 mg/kg bw of extract, did not also cause any mortality or significant change in body weight, relative weight of vital organs. Furthermore, hematological and biochemical parameters and histopathological examination did not show any significant change. The observed decrease in blood glucose levels did not correlate with organ damage and supports the safety of the plant. However, the reduction of LDL-cholesterol has shown that the extract can prevent cardiovascular disease.Conclusions: This finding demonstrated thatA. spinosusroot is non-toxic with a LD50 > 5000 mg/kg bw. Thus, the extract can be used for cutaneous and subchronic oral administration at doses ≤ 1000 mg/kg bw. However, further studies such as embryo/fetotoxicity, genotoxicity and neurotoxicity will be needed to prove the safety of chronic administration of the extract in patients and fetuses.
- Open Access
- 17 May 2021
- Published by Springer Nature in Bulletin of the National Research Centre
- Vol. 45 (1) , 1-9
In vitro study of protective effect of Pterocarpus erinaceus Poir. stem bark and Amaranthus spinosus L. root extracts on cataractogenesis and glomerulopathy
Background: Cataracts and glomerulopathy are disabling complications of diabetes mellitus. The use of medicinal plants in the treatment of diabetes helps prevent or delay these complications. Pterocarpus erinaceus and Amaranthus spinosus are part of these medicinal plants used in traditional medicine to treat diabetes and its complications. The aim of this study was to evaluate in vitro the protective effect of the dried hydroethanolic extracts of the two plants against cataractogenesis and glomerulopathy induced by high glucose. Lenses and kidney fragments from Sprague–Dawley rats were cultured in artificial aqueous humor and in glomerular solution under high glucose, respectively. The extracts of the two plants at doses of 250 and 500 mg/kg bw were added to the culture medium and incubated for 72 h for the lenses and 96 h for the kidney fragments. Morphological and biochemical parameters were evaluated during the cultures. Results: The lenses treated with extracts of both plants remained shiny and transparent in contrast to the opacity observed in toxic controls. The treatment by extract caused a significant (p < 0.001) decrease in malondialdehyde and a significant increase (p < 0.001) in glutathione and catalase levels in lenses and kidney fragments. The extracts also caused a significant increase (p < 0.0001) in glucose absorption in glomeruli and a decrease in tubular glucose reabsorption in kidney fragments. This led to a decrease in glucose in the incubation medium. Conclusion: These findings showed that the dried hydroethanolic extract of P. erinaceus and A. spinosus can be used to reduce hyperglycemia effects by inhibiting oxidative stress pathways and then preventing or delaying the onset of cataracts and kidney failure in diabetes.
- 17 May 2021
- Published by Springer Nature in Bulletin of the National Research Centre
- Vol. 45 (1) , 1-9
Open AccessIn vitro study of protective effect of Pterocarpus erinaceus Poir. stem bark and Amaranthus spinosus L. root extracts on cataractogenesis and glomerulopathy
Background: Cataracts and glomerulopathy are disabling complications of diabetes mellitus. The use of medicinal plants in the treatment of diabetes helps prevent or delay these complications. Pterocarpus erinaceus and Amaranthus spinosus are part of these medicinal plants used in traditional medicine to treat diabetes and its complications. The aim of this study was to evaluate in vitro the protective effect of the dried hydroethanolic extracts of the two plants against cataractogenesis and glomerulopathy induced by high glucose. Lenses and kidney fragments from Sprague–Dawley rats were cultured in artificial aqueous humor and in glomerular solution under high glucose, respectively. The extracts of the two plants at doses of 250 and 500 mg/kg bw were added to the culture medium and incubated for 72 h for the lenses and 96 h for the kidney fragments. Morphological and biochemical parameters were evaluated during the cultures. Results: The lenses treated with extracts of both plants remained shiny and transparent in contrast to the opacity observed in toxic controls. The treatment by extract caused a significant (p < 0.001) decrease in malondialdehyde and a significant increase (p < 0.001) in glutathione and catalase levels in lenses and kidney fragments. The extracts also caused a significant increase (p < 0.0001) in glucose absorption in glomeruli and a decrease in tubular glucose reabsorption in kidney fragments. This led to a decrease in glucose in the incubation medium. Conclusion: These findings showed that the dried hydroethanolic extract of P. erinaceus and A. spinosus can be used to reduce hyperglycemia effects by inhibiting oxidative stress pathways and then preventing or delaying the onset of cataracts and kidney failure in diabetes.